Clinical Trial: A Preliminary Study About Recurrent Spontaneous Abortion and Repeated Implantation Failure IVF-ET Patients Treated by Active Immunotherapy With Small Amount of Lymphocytes

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Preliminary Study About Recurrent Spontaneous Abortion and Repeated Implantation Failure IVF-ET Patients Treated by Active Immunotherapy With Small Amount of Lymphocytes

Brief Summary: Recurrent spontaneous abortion(RSA) and repeated implantation failure (RIF) during IVF-ET severely affects IVF live birth rate and patient's health.The specific etiology contains chromosomal abnormalities, reproductive anatomical abnormalities, endocrine disorders, reproductive system infections, autoimmune and environmental factors. However there are still 50% to 60% RSA which don't have a clear cause, called unexplained recurrent spontaneous abortion (URSA), mainly related to immune factors.Among various treatments,lymphocytes active immunotherapy is the most common treatment method, and its clinical efficacy is widely recognized although its action mechanism is not clear so far.

Detailed Summary: The main mechanism of active immunotherapy includes upregulating Th2-type cytokines, downregulating Th1-type cytokines, making Th1 / Th2 shift to Th2, inducing maternal serum IL-6 and sIL6R, PIBF, EGF; inducing the expression of Fas / Fasl on lymphocyte surface; increasing the proportion of CD8 + cells, Th2-type cells and CD + CD25 + Treg cells, decreasing the activity of CD56 + CD16 + NK cell and so on.The purpose of this study is to observe the treatment effects of active immunotherapy on RSA and RIF patients. What's more,we will used flow cytometry, and quantitative real-time PCR (qPCR) methods to characterize Th1/Th2 and Th17/Treg cell populations after immunotherapy,ecpecting to find out the exact molecule mechanism of immunotherapy with paternal or third party lymphocytes.
Sponsor: Nanjing University

Current Primary Outcome: Pregnancy rate [ Time Frame: 1 year ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Nanjing University

Dates:
Date Received: March 8, 2017
Date Started: May 2015
Date Completion: December 30, 2017
Last Updated: March 10, 2017
Last Verified: March 2017